Cost–utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis

References

• Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123–130.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Hawker G, Mosher D. The impact of arthritis in Canada: today and over the next 30 years. Arthritis Alliance Can. 2011:1–52.
   Google Scholar
• Bykerk VP, Akhavan P, Hazlewood GS, Canadian Rheumatology Association, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559–1582.
   PubMed Web of Science ®Google Scholar
• Pope JE, Haraoui B, Rampakakis E, on behalf of the Optimization of Adalimumab Trial Investigators, et al. Treating to a target in established active rheumatoid arthritis patients receiving a tumornecrosis factor inhibitor: results from a real-world cluster-randomized Adalimumab trial. Arthritis Care Res.2013;65(9):1401–1409.
   Web of Science ®Google Scholar
• Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012;71(6):845–850.
   PubMed Web of Science ®Google Scholar
• Stoffer MA, Schoels MM, SmolenJS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75(1):16–22.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges, SL, Jr. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Raimondo MG, Becciolini A, et al. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev. 2017;16(12):1185–1195.
   PubMed Web of Science ®Google Scholar
• Todoerti M, Favalli EG, Iannone F, et al. Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology. 2018;57(Suppl 7):vii42–vii53.
   PubMedGoogle Scholar
• Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology. 2019;58(Suppl 1):i43–i54.
   PubMed Web of Science ®Google Scholar
• Choquette D, Bessette L, Haraoui B, et al. Use of rituximab compared to TNFi agents as second and third line therapy in patients with rheumatoid arthritis: 6-year follow-up report from the Rhumadata® clinical database and registry. Arthritis Rheumatol. 2015;67:615–616.
   Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
   Google Scholar
• Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1–278.
   PubMed Web of Science ®Google Scholar
• Pennington B, Davis S. Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results. Value Health. 2014;17(8):762–771.
   PubMed Web of Science ®Google Scholar
• Manders SH, Kievit W, Adang E, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther. 2015;17(1):134.
   PubMedGoogle Scholar
• Joensuu JT, Huoponen S, Aaltonen KJ, et al. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLOS One.2015;10(3):e0119683.
   PubMed Web of Science ®Google Scholar
• Brown S, Everett CC, Naraghi K, et al. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Southampton (UK): NIHR Journals Library; 2018 Jun. (Health Technology Assessment, No. 22.34.); 2019 [cited 2019 Apr 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507299/.
   Google Scholar
• Tsao NW, Bansback NJ, Shojania K, et al. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2012;26(5):659–676.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT. QALYs in 2018-advantages and concerns. JAMA. 2018;319(24):2473–2474.
   PubMed Web of Science ®Google Scholar
• TreeAge Pro. TreeAge Software. Williamstown (MA). Available from: http://www.treeage.com.
   Google Scholar
• Rhumadata. Rhumadata Portail. 2019. Available from: https://rhumadata.info/.
   Google Scholar
• Bruce B, Fries J. The health assessment questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(5 Suppl 39):S14–S18.
   PubMed Web of Science ®Google Scholar
• EQ-5D | EQ-5D Instruments | About EQ-5D [cited 2019 Apr 1]. Available from: https://euroqol.org/.
   Google Scholar
• Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. In: NIHR Health Technology Assessment Programme: Executive Summaries. Southampton (UK): NIHR Journals Library; 2003.
   Google Scholar
• Drummond MF, Barbieri M, Wong J. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Making. 2005;25(5):520–533.
   PubMed Web of Science ®Google Scholar
• Liste de Médicamentspubliéepar la Régie de l’assurancemaladie du Québec. Service des relations avec la clientele.Québec; 2020 [cited 2020 Sep 8]. Available from: https://www.ramq.gouv.qc.ca/sites/default/files/documents/liste-med-2020-07-08-en.pdf.
   Google Scholar
• Régie de l'assurancemaladie du Québec. Médecinsspécialistes–Manuel et guide de facturation [cited 2020 Sep 8]. Available from: http://www.ramq.gouv.qc.ca/fr/professionnels/medecins-specialistes/manuels/Pages/remuneration-acte.aspx.
   Google Scholar
• Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.
   Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: OUP Oxford; 2006.
   Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, ISPOR-SMDM Modeling Good Research Practices Task Force, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDMModeling Good Research Practices Task Force-6. Value Health. 2012;15(6):835–842.
   PubMed Web of Science ®Google Scholar
• StataCorp. Stata Statistical Software: Release 13.College Station(TX): StataCorp LP.; 2013.
   Google Scholar
• SAS [computer program]. Version 9.4. Cary (NC): SAS Institute Inc; 2014.
   Google Scholar
• Pope JE, Khanna D, Norrie D, et al. The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol. 2009;36(2):254–259.
   PubMed Web of Science ®Google Scholar
• Dakin H, Abel L, Burns R, et al. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health Qual Life Outcomes. 2018;16(1):31.
   PubMed Web of Science ®Google Scholar
• Barnabe C, Thanh NX, Ohinmaa A, et al. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis. 2013;72(10):1664–1668.
   PubMed Web of Science ®Google Scholar